News
Current report No. 5/2021 – Dates for submitting periodical reports in 2021
January 29, 2021 Date prepared: 28/01/2021 Subject: Dates for submitting periodical reports in 2021 Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report:Acting pursuant to Article 80 subs. 1 of the Regulation of the Minister of Finance of 29 March 2018Read more »
Current report No. 3/2021 – Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US
Subject: Obtaining a patent for GPR40 receptor agonists and their use in T2D treatment in the US Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information, time: 4:42 PM Content of the report: Management Board of Celon Pharma S.A. (the “Company”) wishes to announce that on January 18, 2021,Read more »
Current report No. 2/2021 – The National Centre for Research and Development recommended co-funding of the project dedicated to the development of a drug based on GPR40 receptor agonists in the treatment of neuropathic pain
Subject: The National Centre for Research and Development recommended co-funding of the project dedicated to the development of a drug based on GPR40 receptor agonists in the treatment of neuropathic pain Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information, time: 4:27 PM Content of the report: Management BoardRead more »
Celon Pharma at Top Picks by Trigon Investor Conference
On January 21, 2021, representatives of the Company’s Management Board will take part in the Top Picks by Trigon conference. Celon Pharma was among 21 companies recommended by Trigon DM in 2021.
Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression
Jan 8, 2020—Celon Pharma ($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation) in acute phase of treatment-resistant bipolar depression. View the webcast from TC See the presentation from the Meeting. In the trial, Falkieri met the primary endpoint with statistically significant reductions in MADRS total scoreRead more »
Current report No. 1/2021 – Positive results of the phase II clinical trial on Celon Pharma’s DPI esketamine in bipolar treatment-resistant depression [03KET2018]
Date prepared: 01/08/2021, 7:23 PM Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – confidential information. Content of the report: In relation to the current report No. 45/2020 regarding the date for the presentation of results of the phase II clinical trial on esketamine-based DPI drug (Falkieri) in bipolar treatment-resistant depression,Read more »
Celon Pharma at J.P. Morgan Annual Healthcare Conference DIGITAL 11-14 January 2021 .
This year, company taking meetings via the Bio Partnering platform during the week of the JP Morgan Healthcare Conference, but will also take part in meetings with foreign investors. Maciej Wieczorek, CEO of Celon Pharma: We have an intensive week of meetings and presentations ahead of us. This year, we use our presence at JPRead more »
Celon Pharma at Jefferies Virtual London Healthcare Conference
The Company’s representatives will take part in the largest pharmaceutical conference in Europe. Maciej Wieczorek, CEO of Celon Pharma S.A.: We are increasing the presence of our products abroad, building a strong position in the segment of inhalation products on the global pharmaceutical market; we are observing that companies from around the world are takingRead more »
The power of science, passion and innovation – video material and on line meeting
Video about R&D Centre with transcript.